TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific).

imperial-TCT 2018This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or 4) and native superficial femoral artery or proximal popliteal artery lesions.

 

The primary efficacy endpoint was primary vessel patency as determined by Doppler echocardiography at 12 months after the procedure. The primary safety endpoint was all-cause death, target-limb amputation, or repeat revascularization, at 12 months.

 

The trial included 465 patients randomized 2:1 (Eluvia n = 309 and Zilver PTX n = 156). Primary patency in the Eluvia group was 86.8% vs. 81.5% in the Zilver PTX group, thus achieving non-inferiority. The device was also non-inferior as regards safety; there were no deaths and one amputation at 13 months in the Eluvia group, and one revascularization in each group.


Read also: New Atrial Fibrillation After TAVR Indicates Prognosis.


A post hoc analysis showed that, at 9 months, patency in the Eluvia group was superior and the trend towards thrombosis was lower (about 50% less, although the comparison included few patients).

 

Original title: Twelve-Month Results of the IMPERIAL Randomized Trial: Comparing the Eluvia and Zilver PTX Stents for Treatment of Femoropopliteal Arteries.

Presenter: William A. Gray.

 

IMPERIAL-presentacion

IMPERIAL-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....